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Sulnlllal'y 
Vascular permeability factor (VPF, also known as vascular endothelial growth factor or VEGF), 
is a potent microvascular permeability enhancing cytokine and a selective mitogen for endothelial 
cells. It has been implicated in tumor angiogenesis and ascites fluid accumulation. Since development 
of the destructive synovial pannus in rheumatoid arthritis (RA) is associated with changes in 
vascular permeability (synovial fluid accumulation), synovial cell hyperplasia, and angiogenesis, 
we examined synovial fluids (SFs) and joint tissue for the expression and local accumulation of 
VPF/VEGF. VPF/VEGF was detected in all of 21 synovial fluids examined and when measured 
by an immunofluorimetric assay, ranged from 6.9  to  180.5  pM.  These levels are biologically 
significant, since <1 pM VPF/VEGF can elicit responses from its target cells, endothelial cells. 
Levels of VPF/VEGF were highest in rheumatoid arthritis fluids (n  =  10), with a mean value 
(+_  SEM) of 59.1  _+  18.0 pM, vs. 21.4  +_  2.3  pM for 11 SFs from patients with other forms 
of arthritis (p  =  0.042). In situ hybridization studies that were performed on joint tissues from 
patients with active RA revealed that synovial lining macrophages strongly expressed VPF/VEGF 
mRNA, and that microvascular endothelial cells of nearby blood vessels strongly expressed mRNA 
for the VPF/VEGF receptors, fit-1  and KDR.  Immunohistochemistry performed on inflamed 
rheumatoid synovial tissue revealed that the VPF/VEGF peptide was localized to macrophages 
within inflamed synovium, as well as to microvascular endothelium, its putative target in the 
tissue.  Together, these findings indicate that VPF/VEGF  may have an important role in the 
pathogenesis of RA. 
V 
ascular permeability factor (VPF) was originally identified 
as a 34-42-kD  peptide secreted by tumor cells (1-3). 
VPF  renders the microvasculature hyperpermeable to  cir- 
culating macromolecules with a potency some 50,000 times 
greater than histamine; it is found in animal and human tumor 
effusions where it may contribute to fluid accumulation (4). 
This protein is also a selective endothelial cell mitogen and 
promotes angiogenesis in vivo, hence its additional name, vas- 
cular endothelial growth factor (VEGF) (5).  To emphasize 
the importance of both these activities,  the term VPF/VEGF 
is used here. 
In addition to its association with tumors, VPF/VEGF is 
expressed in a limited number of sites in normal tissues  (6, 
7) and is upregulated in keratinocytes during wound healing, 
a process that involves microvascular hyperpermeability and 
angiogenesis  (8).  Expression  patterns  of  a  VPF/VEGF- 
receptor, fit-l, correspond very well to sites of VPF/VEGF 
expression in normal tissues  during murine embryonic de- 
velopment and during cutaneous wound healing (9). 
By inducing increased microvascular permeability and en- 
dothelial cell growth, VPF/VEGF may facilitate angiogen- 
esis and tumor stroma formation (6, 10). In fact, neutraliza- 
tion  of VPF/VEGF  with  antibodies  not  only suppresses 
extravasation of plasma proteins in vivo (2) but also inhibits 
tumor growth in vivo (11). In situ hybridization studies have 
demonstrated VPF/VEGF expression in a variety of trans- 
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the  expression  of  specific  endothelial  cell  receptors  for 
VPF/VEGF (KDR and fit-l) is simultaneously upregulated 
in nearby blood-vessel endothelium  in tumors  (1). 
The hyperplastic synovial pannus in rheumatoid arthritis 
resembles a solid tumor in certain ways, especially in its in- 
trinsic cellular proliferation, its invasive properties and the 
association of angiogenesis with the development of this highly 
vascularized tissue (12). Pharmacological inhibition of angio- 
genesis is known to block experimental arthritis  (collagen- 
induced arthritis) (13). Inflammatory arthritis is also charac- 
terized by the accumulation of synovial fluids (SFs), an effusion 
rich in plasma proteins. These facts taken together suggested 
to us that VPF/VEGF might have a role in the pathogenesis 
of arthritis. 
Materials and Methods 
Human SFs and  Joint Biopsies.  SFs were collected by aspiration 
from patients with a variety of arthritides. Total white ceU counts 
were performed and the fluids were centrifuged at 2,500 rpm for 
15 min to pellet cells and particulate matter. Aliquots of the super- 
natants were stored at  -70~  Differential cell counts were not 
performed. Synovial tissue was from wrist synovectomies (n  =  4) 
or hips (n  =  2) for the rheumatoid arthritis specimens  and from 
a hip (n =  1) for osteoarthritis.  Patients ranged from 40-65 yr of age. 
Assays  for VPF/VEGF and Rheuma~'d Factor  in SFs.  VPF/VEGF 
was measured with a sensitive and highly specific immunofluori- 
metric assay, similar  to a sandwich ELISA (14). Briefly, antibody 
directed against a COOH-terminal peptide of human VPF/VEGF 
was immobilized on microtitre plates; SFs containing VPF/VEGF 
(or standards or control buffer) were allowed to bind, and the plates 
washed. Bound VPF/VEGF was detected with a second antibody 
directed against an NH2-terminal peptide of VPF/VEGF, labeled 
with Eu3+-chelate.  Fluorescence was  detected as described (14). 
Human recombinant VPF/VEGF, kindly provided by Dr. Steven 
R. Ledbetter (The Upjohn Company, Kalamazoo, MI), was em- 
ployed as a standard. 
Rheumatoid factor was assayed by ELISA as previously described 
using  as  a  standard,  a  monodonal  IgM  (x)  isolated  from  a 
cryoprecipitate (15,  16). Rheumatoid factor assays were used to 
confirm diagnoses and to assess possible interference with measure- 
ment of VPF/VEGF. 
In Situ Hybridization (ISH) and Immunohistockemistry (IH).  Re- 
agents were prepared with diethypyrocarbonate-treated PBS. Sy- 
novial  biopsies  were  fixed in  4%  paraformaldehyde-phosphate 
buffered saline,  pH 7.4 (PBS),  for 2-4 h at 4~  and were then 
transferred to 30% sucrose-PBS overnight at 4~  frozen in OCT 
compound (Miles Diagnostics, Elkhart, IN) and stored at -70~ 
ISH was performed on 6 #m frozen tissue sections.  Selection and 
preparation of the antisense and sense (control) single stranded 
riboprobes for VPF/VEGF, and for the VPF/VEGF endothelial cell 
receptors fit-1 and KDR, have been described (17). The antisense 
VPF/VEGF  probe  hybridizes  specifically  with  a  region  of 
VPF/VEGF  mRNA  common  to  all  four  known  VPF/VEGF 
splicing variants (18,  19). 
The tissue specimens  processed  for ISH were found to also be 
suitable for immunohistological studies. An affinity-purified rabbit 
antibody to the NH2-terminal peptide (amino acid residues  1-26) 
of human VPF/VEGF was used in IH (and as the second anti- 
body in  the VPF/VEGF immunoassay) and its preparation has 
been described  (10,  20).  This  antipeptide  antibody  specifically 
binds VPF/VEGF in ELISA assays and on immunoblots, blocks 
VPF/VEGF activity, and, when linked to agarose, selectively ab- 
sorbs VPF/VEGF from solution (20); because of its specificity, it 
has become the antibody of choice for demonstrating VPF/VEGF 
in tissue  sections by IH (10,  17). KP-1,  an antibody specific for 
human macrophages, was purchased from Dako Corp.  (Carpin- 
teria, CA). An antipeptide antibody specific for fibrin was the kind 
gift of Dr. Gary Matsueda (Massachusetts General Hospital, Boston, 
MA); this antibody is directed against the NH2-terminal portion 
of the fibrin B chain and does not recognize fibrinogen (21). IH 
was performed with an avidin-biotin  peroxidase conjugate protocol 
(10, 22). Normal rabbit IgG diluted to an equivalent protein con- 
centration was used as a control instead  of the primary antibody. 
Western Blotting of Human VPF/VEGF and Synovial Tissue Ex- 
tract.  Human recombinant VPF/VEGF was purchased from R&D 
Systems, Inc. (Minneapolis,  MN). An extract of human rheuma- 
toid arthritis (RA) synovial tissue was made by homogenizing 30-40 
mg of tissue in 3 ml ice cold 20 mM Tris, 150 mN NaC1, 20 mM 
EDTA buffer, pH 7.5. The extracts were centrifuged 5 min at 12,000 
rpm in a microfuge to remove particulates,  the protein content de- 
termined, and aliquots were subjected  to 12% SDS-PAGE under 
reducing conditions. 
Into individual lanes were loaded either 8/~g total synovial tissue 
extract, 12 ng human recombinant VPF/VEGF (with BSA carrier 
protein), or 8 #g of tissue extract spiked with 12 ng VPF/VEGF. 
The proteins  were  subjected  to  SDS-PAGE  and  transferred  to 
nitrocellulose paper. Replicate lanes were examined by silver staining. 
After the transfer the nitrocellulose "blot" was blocked with 10% 
milk protein, incubated with a 1:200 dilution of the affinity purified 
anti-VPF/VEGF in PBS, and then subjected  to biotin/avidin en- 
hanced peroxidase detection (Vector Laboratories Inc., Burlingame, 
CA).  The substrate was  3,3-diaminobenzidine. 
Results and Discussion 
Immunoassay of VPF/VEGF in Synovial Fluids.  Immuno- 
fluorimetric analysis revealed detectable VPF/VEGF in all SFs 
examined from 21 patients with various forms of arthritis; 
values ranged from 6.9 to 180.5 pM (Table 1).  The highest 
levels of VPF/VEGF were found in SFs taken from patients 
with clinically well-documented RA.  Although  there was 
Table  1.  VPF/VEGF Concentration in Synot~ial Fluids 
Diagnosis  Range  Mean  _+ SEM  Median 
pM  pM 
RA*  (n  =  10)  (6.9-180.5)  59.1  _+  19.0  42.2 
OA  (n  =  3)  (24.9-36.0)  29.5  +  3.4  27.5 
Gout  (n  =  3)  (8.5-24.8)  17.4  _+  4.8  18.9 
Misc3  (n  =  5)  (12.9-23.5)  17.7  _+ 3.3  22.1 
All of seven fluids that had VPF/VEGF levels >40 pM were from pa- 
tients with RA (p <0.001; Fisher's exact test). OA, osteoarthritis. 
* The mean of the VPF/VEGF values in RA fluids was significantly  differ- 
ent from the means of SFs with all other diagnoses (p  =  0.042). 
* Miscellaneous diagnoses included: psoriatic arthritis (n  =  I), avascu- 
lar necrosis (n  =  1), trauma (n  =  1), and unknown (n  =  2). 
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in the SFs of patients diagnosed as having RA than in those 
of patients with other forms of arthritis (p  =  0.04).  How- 
ever,  the levels of VPF/VEGF  measured in all of the joint 
fluids  studied  may  well  have biological  significance  since 
VPF/VEGF  levels  as  low  as  ~0.2  pM  are effective in  ac- 
tivating cultured endothelial cells (23). Total white cell counts 
were performed on all SFs but these did not correlate well 
with VPF/VEGF  levels  (r  =  0.174; p  =  0.5).  Differential 
cell counts were not performed; it is not yet known whether 
VPF/VEGF levels correlate well with a specific cell type, as 
previously shown for monocyte/macrophages in inflamma- 
tory fluids  (4). 
Histology of  Synovial Biopsies:  Expression of VPF/VEGF and 
Its Receptors.  Synovial biopsies were available  from six pa- 
tients with RA and from one with osteoarthritis.  Biopsies 
from three of the patients with RA revealed hyperplastic, 
inflamed synovial tissue (pannus), characterized histologically 
by extensive infiltration  of lymphocytes, macrophages and 
plasma cells, fibrin deposition, and increased numbers of new 
blood vessels lined by hypertrophic endothelium (Fig. 1). Fi- 
brin, positively identified by immunohistochemistry, was most 
abundant superficially near the synovial surface and to a lesser 
extent in deeper zones (Fig. 1, E  and F). Synovial tissue bi- 
opsied from the three other patients with a clinical diagnosis 
of RA revealed no significant inflammation; i.e., inactive dis- 
ease. Joint tissue from the single case of osteoarthritis was 
hyperplastic but  contained only rare inflammatory cells. 
In situ hybridization performed on two of the three pa- 
tients with active RA revealed a population of synovial lining 
cells that labeled intensely for VPF/VEGF mRNA; positive 
cells had morphological features of synovial macrophages (Fig. 
2, A  and B). Occasional inflammatory cells more deeply situ- 
ated in pannus, also having morphological features of mac- 
rophages, labeled for VPF/VEGF but less intensely than mac- 
rophages closer to the synovial surface. In addition, vascular 
endothelial cells of small pannus blood vessels labeled intensely 
for the mRNAs of both VPF/VEGF receptors, fit-1 and KDR 
(Fig.  2, E-H).  In synovium from a third RA patient,  the 
lining layer was not present; but, an inflammatory infiltrate 
Figure  1.  Immunohistochemical staining of inflamed  synovial tissue 
(pannus)  from a patient with active RA. A population of cells near the 
synovial surface stains strongly for VPF/VEGF (tl) and also for the mac- 
rophage marker KP-1 (B). Endothelial cells lining adjacent small vessels 
(two are labded v) stain with antibodies against VPF/VEGF (C) but do 
not stain with a control antibody (D). Low power (E) and higher power 
(F) photomicrographs demonstrate fibrin deposits concentrated at the sy- 
novial surface.  Original magnifications: A-D and F,  x279; E,  x107. 
Figure  2.  In situ hybridization of inflamed synovial tissue from a pa- 
tient with active RA, illustrated in photomicrographs of the same fields 
in brightfidd (A, C, and G) and darkfield (B, D, and H). (,4 and B) In- 
tense labeling with a probe for VPF/VEGF mRNA of a population of 
synovial lining cells having the morphology of macrophages.  (C and D) 
Background with control VPF/VEGH sense probes was consistently low. 
(E-H)  Endothelial cells in small vessds near the synovial  surface label 
strongly for mtLNAs of the VPF/VEGF receptors fit-1 (E and F) and KDR 
(G and H).  Original magnifications:  x288. 
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was found to express KDK mRNA. 
In contrast, in the noninflamed synovia available  from three 
other patients  with RA and in the single case of osteoar- 
thritis, specific  labeling was not observed with antisense  probes 
to VPF/VEGF or to VPF/VEGF receptor mRNAs. Back- 
ground labeling with sense (control) probes was consistently 
low in all tissues examined (Fig. 2,  C  and D). 
Immunohistochemical Detection of VPF/VEGF Protein in 
Pannus.  In biopsies from patients  with active RA, immu- 
nostaining with antibodies to VPF/VEGF revealed a popula- 
tion of cells similar in morphology, frequency and distribu- 
tion to those identified as expressing VPF/VEGF mKNA; 
this cell population also stained for KP-1, a marker for cells 
of macrophage lineage (Fig. 1, A  and B) (24). 
Endothelial cells of small blood vessels in pannus also stained 
for VPF/VEGF in the patients  with active RA (Fig.  1,  C 
and D). As noted above, endothelium of vessels in the same 
specimens did not express VPF/VEGF mRNA (as detected 
by in situ  hybridization)  but did express mRNA for both 
of the VPF/VEGF-receptors  examined. 
In sections of synovial tissue from a patient with osteoar- 
thritis,  there was no significant inflammatory cell infiltra- 
tion; nonetheless, very rare synovial macrophages stained for 
VPF/VEGF (not shown). Background immunostaining with 
IgG control antibodies  was always insignificant. 
To demonstrate the specificity  of  the anti-VPF/VEGF used 
in the immuno-staining  procedure shown in Fig. 1, a Western 
blot was performed with pure recombinant VPF/VEGF and 
synovial tissue extracts (Fig. 3). VPF/VEGF was not present 
in sufficient amount to detect in the tissue extract,  as ex- 
pected, since overall only a relatively small proportion of  cells 
of  the tissue contained VPF/VEGF mRNA (as shown in Fig. 
1). However,  12 ng of purified VPF/VEGF was readily de- 
tected by the anti-VPF/VEGF antibody,  either alone (Fig. 
3, lane 5) or combined with the synovial tissue extract (Fig. 
Figure  3.  Western blotting of synovial tissue extract and human recom- 
binant VPF/VEGE Lanes 1-3, silver stained 12% SDS-PAGE; Lanes 4-6, 
nitrocellulose transfer of replicate gel immunostained with affinity purified 
anti-VPF/VEGF. Lanes (I and 4), 8/zg synovial tissue  extract; lanes (2 
and 5), 12 ng VPF/VEGF with BSA carrier protein; lanes (3 and 6), 8 #g 
synovial  tissue extract plus 12 ng VPF/VEGF. 
3,  lane 6).  Even though present  at at 600-fold excess over 
VPF/VEGF,  there was no significant recognition of other 
tissue proteins  by the anti-VPF/VEGF in this procedure. 
VPF/VEGF Expression and the Pathogenesis of RA.  The 
data presented indicate that VPF/VEGF mRNA is expressed 
by synovial macrophages in patients with active RA and fur- 
thermore, that VPF/VEGF protein is found in the cytoplasm 
of  these macrophages, as well as in association  with endothelial 
cells lining nearby blood vessels. In addition,  mRNAs for 
the two best characterized VPF/VEGF receptors, fit-1 and 
KDR, are expressed by microvascular endothelial cells that 
stain with antibodies  to VPF/VEGF.  These findings were 
absent in patients  with clinically inactive disease. 
The simplest explanation of  these data is that in active RA 
synovial macrophages are stimulated  to synthesize and se- 
crete VPF/VEGF;  secreted VPF/VEGF binds to local blood 
vessel endothelium by way of specific receptors and also ex- 
travasates into the  joint cavity. Binding of  VPF/VEGF renders 
the endothelium of small blood vessels hyperpermeable to 
plasma proteins, which leak into the  joint cavity, producing 
a protein-rich effusion. Extravasated fibrinogen has been pre- 
viously demonstrated in synovial tissues where it may con- 
tribute to the fibrin deposition  found in rheumatoid syno- 
vium (but not osteoarthritis)  (25, 26). This fibrin may serve 
as a potent stimulus  for angiogenesis in this region of the 
RA synovium,  as has been already shown in other tissues 
(27). A similar sequence of events is encountered in wound 
healing, where tissue fibrin deposits are replaced by highly 
vascular granulation tissue that closely resembles pannus (8). 
These events also echo those found in many tumors, where 
expression of both VPF/VEGF and its receptors (fit-1 and 
KDR) are strikingly upregulated and have been implicated 
in tumor angiogenesis and stroma formation (1, 28). 
VPF/VEGF was also found in the SFs of patients  with 
other forms of arthritis besides RA. Although the amounts 
of VPF/VEGF present were significantly lower than those 
found in RA, they were still more than sufficient to effect 
biological activity. It is noteworthy that the fibrin deposi- 
tion demonstrated in rheumatoid synovium is not found in 
other forms of arthritis  (26), and may help explain why an- 
giogenesis is primarily a feature of the hyperplastic rheuma- 
toid synovium, even  though VPF/VEGF was found in gout, 
osteoarthritis,  and other types of synovial fluids. 
It is not known, at present, what regulates the increased 
expression of VPF/VEGF by synovial macrophages in RA. 
Earlier studies indicated that oil-induced peritoneal  macro- 
phages, but not resident peritoneal or alveolar macrophages, 
expressed  levels  of  VPF/VEGF mRNA detectable  by Northern 
analysis or ISH (6). However, little is known about the regu- 
lation of VPF/VEGF expression in macrophages. A number 
of cytokines have been demonstrated in synovial fluids and 
tissue of RA patients,  including TNF,  TGF-/~, and  IL-1 
(29-31); it is possible that one or more of these may have 
induced VPF/VEGF expression in synovial macrophages. It 
is not yet known whether VPF/VEGF can induce expres- 
sion of such cytokines in macrophages or endothelial cells. 
In summary, it appears that VPF/VEGF is synthesized and 
344  VPF/VEGF  in Synovial Angiogenesis  in Arthritis secreted by macrophages in actively inflamed KA synovial 
tissue and that secreted VPF/VEGF binds to specific receptors 
on endothelial cells of small nearby blood vessels. In view 
of the fact that both KDR and fit-1 are class III tyrosine ki- 
nase receptors  (32),  it  is probably relevant  that phospho- 
tyrosine, the product of activated tyrosine-kinase receptors, 
has recently been demonstrated in vascular endothelium of 
rheumatoid synovium (33). VPF/VEGF appears in some ways 
to resemble other proangiogenic cytokines that have been im- 
plicated in synovial angiogenesis (fibroblast growth factor, 
IL-8) (34, 35),  but with the rather unique attributes of in- 
ducibility by hypoxia (36) (a feature of arthritic joint tissue), 
the ability to induce vascular permeability, and a restricted 
mitogenic activity for endothelial cells. 
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